Showing 2051-2060 of 4458 results for "".
Growth Potential of the Aesthetic Market
https://practicaldermatology.com/videos/c-suite-chats/growth-potential-of-the-aesthetic-market/29746/Merz Aesthetics President, North America, Patrick Urban discusses why he expects demand for aesthetic treatments to continue increasing and how to capitalize on it.DermWireTV: Meet Crown Aesthetics, Revance to Market Teoxane Fillers, Almirall Collaborates
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-meet-crown-aesthetics-revance-to-market-teoxane-fillers-almirall-collaborates/19719/On the heels of recent acquisitions, Crown Laboratories is reorganizing and rebranding as three divisions: Crown Aesthetics, Crown Beauty, and Crown Therapeutics. Revance gains immediate and exclusive rights to commercialize Teoxane’s RHA 2, RHA 3, and RHA 4 products, which include lidocaine.DermwireTV — Sun Rises, ICD-10 is Delayed…Again
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-mdash-sun-rises-icd-10-is-delayed-again/19139/In this week's DermwireTV, Sun acquires Ranbaxy, ICD-10 gets unexpectedly delayed, and Murad Alam recaps the ASLMS conference.DermwireTV — Valeant Ups Allergan Bid, Nestle Buys Injectables, and Allergan Makes Its Case
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-mdash-valeant-ups-allergan-bid-nestle-buys-injectables-and-allergan-makes-its-case/19128/BREAKING NEWS: Valeant has increased its offer for Allergan to $72 per share. Read more. Valeant sells the rights to its aesthetic injectables to Nestle, while Allergan touts physician support and challenges Valeant's business model. In this week's edition of DermWireTV, learn about Valeant's latesDermwireTV — Revance’s Neurotoxin Promising, Celebs Fight Melanoma with L’Oreal
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-mdash-revance-rsquo-s-neurotoxin-promising-celebs-fight-melanoma-with-l-rsquo-oreal/19138/In this weeks DermwireTV, patient safety is explored, L'Oreal supports melanoma research and Revance reports positive data for novel neurotoxin.DermwireTV — Nestle acquires Galderma; Dermatologic procedures surge
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-mdash-nestle-acquires-galderma-dermatologic-procedures-surge/19157/In this edition of DermWireTV, from the publishers of Practical Dermatology® magazine: Nestle acquires Galderma, dermatologic procedures surge, and we look ahead to the annual meeting in Denver. #DermWireDermwireTV — A big name is getting bigger; ICD-10 looms
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-mdash-a-big-name-is-getting-bigger-icd-10-looms/19163/In this premiere edition of DermWireTV, from the publishers of Practical Dermatology® magazine, we take a look at the latest acquisition by Valeant Pharmaceuticals, Inc., explore new data for Galderma's Mirvaso for rosacea, and get insights on the ICD-10 code set transition. #DermWireInnovations in the Aesthetic Market and Wrinkle Removal Technology
https://practicaldermatology.com/series/c-suite-chats/innovations-aesthetic-market-and-wrinkle-removal-technology/26732/Lou Scafuri, CEO of SofWave Medical, talks about what makes the company’s Synchronous Ultrasound Parallel Beam technology unique.Clascoterone: A Novel Topical Anti-androgen for the Treatment of Acne
https://practicaldermatology.com/columns/clinical-focus-1/clascoterone-a-novel-topical-anti-androgen-for-the-treatment-of-acne/23133/For the first time in almost 15 years, a new chemical entity may be coming to the market for the topical treatment of acne vulgaris.I Don't Want New Patients! Here's Why
https://practicaldermatology.com/topics/practice-management/i-dont-want-new-patients-heres-why/20423/Why spend your hard-earned marketing dollars trying to convince people who have never heard of you to come try out a service?